Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset

The prognostic value of KRAS mutations in colon adenocarcinoma is controversial. We examined this question as an ancillary study of the PETACC8 phase III trial. We analyzed the pronostic impact of KRAS exon 2 mutations in stage III colon cancer patients (n = 1657) receiving adjuvant FOLFOX ± cetuxim...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2014-12, Vol.25 (12), p.2378-2385
Hauptverfasser:	Blons, H., Emile, J.F., Le Malicot, K., Julié, C., Zaanan, A., Tabernero, J., Mini, E., Folprecht, G., Van Laethem, J.L., Thaler, J., Bridgewater, J., Nørgård-Petersen, L., Van Cutsem, E., Lepage, C., Zawadi, M.A., Salazar, R., Laurent-Puig, P., Taieb, J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Cetuximab Colonic Neoplasms - drug therapy Colonic Neoplasms - genetics colorectal cancer distal colon Exons Female Fluorouracil Gastroenterology. Liver. Pancreas. Abdomen Genes, ras Humans KRAS mutation Leucovorin Male Medical sciences Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Mutation Organoplatinum Compounds Pharmacology. Drug treatments Prognosis Proto-Oncogene Proteins B-raf - genetics proximal colon Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!